ANDREA M. JUDY

• Joined startup as one of 27 inaugural Institutional Sales Specialists across the country for an FDA fast tracked, breakthrough therapy designated product's launch
• Launched sub-lingual form of an Alpha 2 receptor agonist for Adults with Acute agitation associated with Bipolar and Schizophrenia in the institutional and Behavioral health spaces
• Worked with Nurses, physicians, Department Chairs, Medical Directors, and Directors of pharmacy to bring awareness of IGALMI to institutions and drive advocacy for orders and formulary additions
• Collaboration with cross functional teams of Corporate account directors, Medical Managed care, and Marketing to gain or provide access to key customers
• Appointed to the Vice President's Council for 2022-2023 to provide field based input on various company related topics and initiatives
• Strategically rolled out Hospital free trial program to chosen key accounts which led to immediate orders

• Successfully launched Lokelma to Nephrologists, Cardiologists, Internists, Emergency Departments, as well as areas in hospitals including key Department heads and Directors.
• Strategically planned pre-launch activities ensuring access to key targets with effective messaging to quickly gain market share.
• Identified potential business opportunities across multiple specialties outside of nephrology to cultivate growth and ensure long term utilization by additional targets.
• Successfully partnered with key influencers and stakeholders to ensure Lokelma received formulary review inside hospitals allowing patients full access.
• Launched new Chronic Kidney Disease indication for Farxiga to Nephrologists growing marketshare exponentially in that segment.
• Quickly secured in-patient formulary approval at Beaumont Health System and Henry Ford Health System, two of the largest systems in Southeast Michigan.
• Worked with pharmacy and IT to implement an order set be added in the system for Lokelma.
• Partnered with the Nephrology teams to design a hyperkalemia in-patient protocol for Lokelma.

• Marketed and sold Ranexa to interventional and clinical cardiologists as well as high-volume primary care physicians throughout Metro Detroit, spearheading the full sales cycle while continuously bolstering market share quarter-to-quarter.
• Surpassed regional and national averages for TRx performance, securing ranking of up to #39 out of 151 therapeutic specialists through excellence in customer relationship management.
• Forged new relationships and built rapport with key physicians and support staff within a new territory based on lead generation and prospecting capabilities.
• Obtained recognition as the MVP of Ranexa's new-hire sales training class, leveraging expansive industry expertise to obtain in-depth product proficiency.
• Established repute as a high-performing representative based on performance to goal as well as recognition as winner of the 2018 “More Hearts to Help” NRx market share growth contest.

• Promoted the oral anti-platelet Brilinta and statin Crestor within hospitals and clinics in Metro Detroit with targeted call points including interventional cardiologists, clinical cardiologists, cardiology fellows, emergency departments, inpatient and outpatient pharmacies, section chiefs, mid-levels, hospitalists, and residents.
• Collaborated in developing a “STEMI” Protocol alongside the Chiefs of Emergency Medicine, Cardiology, and Cardiovascular Surgery for patients upon arrival to St. John Hospital ER.
• Contributed to the successful design and pull through of the protocol beginning with St. John Hospital & Medical Center (SJHMC), Detroit. Eventually making it a statewide system protocol.
• Initiated the upload of a non-branded ACS patient education video from AstraZeneca's library of materials for display in every cardiac patient room at SJHMC.
• Pulled through STEMI protocol from St. John Hospital & Medical Center to St. John Providence, Providence Park, and Beaumont Grosse Pointe throughout a one-year period.
• Secured “Brilinta First” Protocol for STEMI at Botsford Hospital through collaboration with key cardiologists and emergency room physicians, advancing AstraZeneca's presence on cardiac floors.
• Frequently conducted in-services with physicians and staff to advance product awareness and education, employing creative approaches to reach all shifts, including nights and weekends, in order to strengthen engagement.
• Developed a local speaker into a well-respected national thought leader recognized for the second-highest utilization in the country, rapidly expanding speaking presence from Metro Detroit to the Midwest.

• Spearheaded the sale of Brilinta, Crestor, Toprol-XL, Zestril, and Atacand throughout Metro Detroit.
• Launched and marketed Brilinta, which is first-in-class for acute coronary syndrome (ACS), and secured market share among targeted cardiologists; partnered with emergency departments for initiation, cardiology fellows for transition, and discharge personnel as well as hospital pharmacies to ensure accessibility and affordability.
• Championed the launch of Crestor to Cardiologists, Endocrinologists, and PCP's.
• Received delegation of Crestor training champion for all pre-launch preparations including peer education on market and disease state.
• Captured formulary access for both Crestor and Brilinta throughout the entire Ascension St. John system.
• Earned nomination of cardiovascular lead and expert for the Detroit division.
• Served as the National Convention delegate for the American Heart Association and American College of Cardiology meetings.

President, Alpha Kappa Sigma Sorority